Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer

Anticancer Research

Volumn 19, Issue 2 B, 1999, Pages 1363-1368

  Spila, Antonella ^a   Ferroni, Patrizia ^b   Cosimelli, Maurizio ^a   D'Alessandro, Roberta ^a   Carone, Maria Daniela ^a   Aloe, Simona ^a   Tedesco, Manfredo ^a   Mancini, Raffaello ^a   Casale, Vincenzo ^a   Carlini, Sandro ^a   Casciani, Carlo Umberto ^c   Roselli, Mario ^c   Guadagni, Fiorella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CA 242; Clinical application; Colorectal cancer; Serum tumor markers

Indexed keywords

CA 242 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032994262     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Johansson C, Nilsson O and Lindholm L: Comparison of serological expression of different epitopes on the CA 50-carrying antigen CanAg. Int J Cancer 48: 757-763, 1991.
2. a epitope on distinct core proteins. J Biol Chem 266: 21537-21547, 1991.
3. Johansson C, Nilsson O, Baeckström D, Jansson El and Lindholm L: Novel epitopes on the CA 50-carrying antigen: chemical and immunochemical studies. Tumor Biol 12: 159-179, 1991.
4. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andrin-Sandberg C and Lindholm L: Sensitivity and specificity of CA 242 in gastro-intestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Br J Cancer 65: 215-221, 1992.
5. Kuusela P, Haglund C and Roberts PJ: Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 63: 636-640, 1991.
6. Hall NR, Finan PJ, Stephenson BM, Purves DA and Cooper EH: The role of CA 242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 70: 549-553, 1994.
7. Carpelan-Holmström M, Haglund C, Kuusela P, Järvinen H and Roberts PJ: Preoperative serum levels of CEA and CA 242 in colorectal cancer. Br J Cancer 71: 868-872, 1995.
8. von Kleist S, Hesse Y and Kananeeh H: Comparative evaluation of four tumor markers, CA 242, CA 19-9, TPA, and CEA in carcinomas of the colon. Anticancer Res 16: 2325-2332, 1996.
9. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Pentillä I and Alhava E: Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Br J Cancer 65: 731-734, 1992.
10. Röhtlin MA, Joller H and Largiader F: CA 242 is a new tumor marker for pancreatic cancer. Cancer 71: 701-707, 1993.
11. Haglund C, Lundin J, Kuusela P and Roberts PJ: A new tumor marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70: 487-492, 1994.
12. Lindmark G, Bergström R, Påhlman L and Glimelius B: The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 71: 1090-1094, 1995.
13. Carpelan-Holmström M, Haglund C, Lundin J, Järvinen H and Roberts PJ: Preoperative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur J Cancer 32A: 1156-1161, 1996.
14. Carpelan-Holmström M, Haglund C, Alfthan H, Stenman UH and Roberts PJ: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 74: 925-929, 1996.
15. Lundin J, Roberts PJ, Kuusela P and Haglund C: Prognostic significance of serum CA 242 in pancreatic cancer. A.comparison with CA 19-9. Anticancer Res 15: 2181-2186, 1995.
16. Dahlin U, Karlsson B, Lindholm L and Nilsson O: Development of an enzyme immunoassay for detemination of the tumor associated antigen CA 242. J Tumor Marker Oncol 8: 111-116, 1993.
17. Moertel CG, O'Fallou Jr, Go VLW, O'Connel MJ and Thyant GS: The preoperative carcinoembryonic test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 58: 603-610, 1986.
18. Sikorska H, Shuster J and Gold P: Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 12: 321-355, 1988.
19. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavaliere R, Colcher D, Greiner JW and Schlom J: Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. Cancer 68: 2443-2450, 1991.
20. Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner JW and Schlom J: CA 72-4 measurement of tumor-associated glycoprotein-72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res 52: 1222-1227, 1992.
21. Herlyn M, Sears HF, Steplewski Z and Koprowski H: Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 2: 135-140, 1982.
22. Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito MR, Greiner JW and Schlom J: TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 72: 2098-2106, 1993.
23. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Casaldi V, Cavaliere F, Carlini M, Garofalo A, Rinaldi G, Santoro E, Greiner JW and Schlom J: Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric cancer. Anticancer Res 13: 2409-2414, 1993.
24. Semjonof A, Hamm M and Rathert P: Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World Urol 11: 218-220, 1993.
25. Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, Tedesco M, Carlini S, D'Alessandro R, Perri P, Casciani CU, Greiner JW, Schlom J and Guadagni F: Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res 16: 2241-2248, 1996.
26. Ward U, Primrose JN, Finan PJ, Perfen TJ, Selby P, Purves DA and Cooper EH: The use of tumour markers CEA, CA 195 and CA 242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67: 1132-1135, 1993.